Common questions about Neo Borocillina Gola Dolore (FAQ)
Q: What are the different forms of Neo Borocillina Gola Dolore (lozenges, spray, etc.)?
A: According to the official product information, Neo Borocillina Gola Dolore is generally available in various forms optimized for local use in the mouth and throat. These dosage forms typically include lozenges, an oral mucosal spray, and in some markets, a mouthwash (collutorio). All forms are designed to deliver the active ingredient directly to the affected area.
Q: Do all the different versions of Neo Borocillina Gola Dolore contain the same active ingredient?
A: Official regulatory documents indicate that the primary forms of the product (lozenges, oral spray, and mouthwash) contain flurbiprofen as the single active pharmaceutical ingredient. Flurbiprofen is classified as a non-steroidal anti-inflammatory drug (NSAID).
Q: Can Neo Borocillina Gola Dolore be used for pain after dental procedures?
A: The product's official indications in certain markets describe the symptomatic treatment of irritative-inflammatory conditions of the oropharyngeal cavity, including pain associated with conservative or extractive dental therapy. This means the product is indicated for localized pain or irritation following routine dental work.
Q: Does Neo Borocillina Gola Dolore cause drowsiness or affect alertness?
A: Official warnings note that the medicine can affect the ability to drive or operate machinery, as side effects such as dizziness or drowsiness may occur. Regulatory documents recommend waiting until the user knows how the medicine affects them before driving or operating machinery.
Q: Is there a risk of stomach upset or stomach irritation from using this product?
A: As an NSAID, the product has documented adverse effects. Nausea, abdominal discomfort, and indigestion (upset stomach) are listed as known systemic reactions. Additionally, oral discomfort, including mouth irritation, is officially classified as a common local side effect.
Q: Can people with a history of stomach ulcers use Neo Borocillina Gola Dolore lozenges or spray?
A: Official documents clearly state that the medicine is contraindicated (is not allowed for use) in patients with active or a history of recurrent peptic ulceration, gastrointestinal bleeding, or perforation related to prior NSAID treatment. This is a critical safety restriction based on the active ingredient, flurbiprofen.
Q: Can people with kidney problems use Neo Borocillina Gola Dolore?
A: The medicine is contraindicated (not allowed for use) in patients with severe renal failure. Official documents state that use in patients with non-severe renal impairment (kidney problems) is advised with caution, as NSAIDs may impact kidney function.
Q: Can the lozenges be taken with food or only on an empty stomach?
A: While official administration instructions do not specify whether to take the lozenges with food, official safety information notes that gastrointestinal discomfort or nausea may occur. Patients who experience such effects often find relief by taking oral medication after a small snack or milky drink.
Q: How quickly does Neo Borocillina Gola Dolore typically start to provide symptom relief?
A: Clinical studies examining the use of the lozenge form have provided data on the timeline for relief. Evidence indicates that the median time to first perceived pain relief in patients with acute sore throat was reported to be approximately 11 minutes.
Q: Is the drug designed for short-term use only, or can it be used for prolonged periods?
A: The product is indicated for short-term symptomatic relief only. Official product information states that the maximum duration of administration is three days. Continuing the use of NSAIDs for prolonged periods may be associated with an increased risk of certain adverse effects.
Q: Is the small amount of ethanol (alcohol) in the spray form considered a safety concern?
A: The oromucosal spray contains a small amount of ethyl alcohol (ethanol) as an excipient. Regulatory documents note that at recommended dosages, the amount of ethanol is considered much lower than the quantity that would cause systemic effects. The amount of alcohol in the spray is not generally expected to cause harm.
Q: Do the sugar-free lozenges contain any ingredients that can affect blood sugar levels?
A: The sugar-free lozenges and the spray contain excipients such as liquid sorbitol. Sorbitol is officially recognized as a source of fructose, which is a concern. For safety reasons, the product is contraindicated (not allowed for use) in patients diagnosed with rare hereditary problems of fructose intolerance.
Q: Does Neo Borocillina Gola Dolore contain lactose or gluten?
A: Official documents mandate that all excipients, including potential allergens like lactose or gluten, be detailed on the product label and in the Patient Information Leaflet (SmPC). If a user has a specific intolerance, it is recommended that the complete list of excipients be verified on the package leaflet or SmPC, as formulation specifics can vary.
Q: Are there any specific warnings for people with heart conditions?
A: The medicine is contraindicated (not allowed for use) in patients with severe heart failure. Official NSAID class warnings state that use in patients with non-severe cardiac conditions, history of heart attack, or unmanaged high blood pressure is advised with caution.
Q: Is it possible to become sensitive to the product if used for too long?
A: Yes, official warnings specifically note that the use of the oral mucosal spray and other forms, especially if prolonged, may give rise to phenomena of sensitization or local irritation in the mouth and throat. If signs of sensitization or local irritation occur, the regulatory guidance is to discontinue use of the product.
Q: Can using the lozenges or spray cause an allergic reaction?
A: Yes, Flurbiprofen is known to potentially cause both localized and systemic allergic reactions. Symptoms can include swelling, rash, or hives. If a user experiences any signs of an allergic reaction, use of the product should be immediately discontinued.
Q: Are there any common local side effects like mouth or tongue irritation?
A: Yes, official safety information classifies oral discomfort as a common side effect. This discomfort can include symptoms such as soreness, a burning sensation, or general irritation in the mouth or throat area.
Q: Does the medicine contain sorbitol, and why might that be a concern for some people?
A: Certain formulations contain sorbitol, which is officially a source of fructose. Its presence is noted as a specific concern for patients diagnosed with rare hereditary fructose intolerance, for whom the product is contraindicated.
Q: Why are the lozenges designed to be dissolved slowly in the mouth?
A: The official instructions require the lozenge to be sucked slowly and moved continuously around the mouth. This specific administration technique is provided to help prevent local irritation in the mouth and throat, ensuring the active ingredient is properly distributed for its localized effect.
Q: Is accidental swallowing of the spray or lozenge harmless, according to official information?
A: The regulatory guidance states that at the recommended doses, swallowing the oral mucosal spray does not cause any harm. This is due to the low quantity of the active ingredient delivered in one localized dose.
Q: Can the spray be used for mouth ulcers (stomatitis) not related to a sore throat?
A: Yes, the official indications for the product often go beyond just pharyngitis (sore throat). In some regulatory contexts, the product is indicated for the symptomatic treatment of irritative-inflammatory conditions such as stomatitis (mouth inflammation/ulcers) and gingivitis, in addition to pharyngitis.
Q: Do the mouthwash and spray versions have different contraindications?
A: The main contraindications (e.g., allergy to NSAIDs, severe organ failure, third trimester of pregnancy) are based on the active ingredient (flurbiprofen) and are generally the same for the mouthwash and spray dosage forms. Minor differences, if any, would be limited to specific warnings related to non-active excipients present in one form but not the other.
